{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:43:03Z","timestamp":1792870983372,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"MoE STAR Grant IISC Banglore","award":["MoE-STARS\/STARS-2\/2023-0040"],"award-info":[{"award-number":["MoE-STARS\/STARS-2\/2023-0040"]}]},{"name":"MoE STAR Grant IISC Banglore","award":["MoE-STARS\/STARS-2\/2023-0040"],"award-info":[{"award-number":["MoE-STARS\/STARS-2\/2023-0040"]}]},{"name":"MoE STAR Grant IISC Banglore","award":["MoE-STARS\/STARS-2\/2023-0040"],"award-info":[{"award-number":["MoE-STARS\/STARS-2\/2023-0040"]}]},{"name":"MoE STAR Grant IISC Banglore","award":["MoE-STARS\/STARS-2\/2023-0040"],"award-info":[{"award-number":["MoE-STARS\/STARS-2\/2023-0040"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54373-8","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:26:07Z","timestamp":1783592767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of PDE10A binding ligands as potential therapeutics for the Parkinson\u2019s disease through a computational approach"],"prefix":"10.1038","volume":"16","author":[{"given":"Bharti","family":"Devi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathima","family":"Nuzha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailash","family":"Jangid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"54373_CR1","first-page":"85","volume":"7","author":"DJ Surmeier","year":"2013","unstructured":"Surmeier, D. J. & Sulzer, D. J. P. Pathol. roadmap Parkinson disease, 7 85\u201391. (2013).","journal-title":"Pathol. roadmap Parkinson disease"},{"key":"54373_CR2","doi-asserted-by":"crossref","unstructured":"Xu, L. J.J.P.s.d. Pu, Alpha-Synuclein in Parkinson\u2019s Disease: From Pathogenetic Dysfunction to Potential Clinical Application, (2016) 1720621. (2016).","DOI":"10.1155\/2016\/1720621"},{"key":"54373_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim, T., Jette, N., Frolkis, A. & Steeves, T. The prevalence of Parkinson\u2019s disease: A systematic review and meta-analysis. Mov. Disord. 29, 1583\u20131590 (2014).","journal-title":"Mov. Disord."},{"key":"54373_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.brainres.2015.06.002","volume":"1628","author":"PJ Barrett","year":"2015","unstructured":"Barrett, P. J. & Greenamyre, J. Post-translational modification of \u03b1-synuclein in Parkinson\u05f3 s disease. Brain Res. 1628, 247\u2013253 (2015).","journal-title":"Brain Res."},{"key":"54373_CR5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/mds.24954","volume":"27","author":"A Siderowf","year":"2012","unstructured":"Siderowf, A. & Lang, A. E. Premotor Parkinson\u2019s disease: Concepts and definitions. Mov. Disord. 27, 608\u2013616 (2012).","journal-title":"Mov. Disord."},{"key":"54373_CR6","doi-asserted-by":"crossref","unstructured":"Valera, E. E.J.J.o.n. Masliah, Therapeutic approaches in Parkinson\u2019s disease and related disorders, 139 346\u2013352. (2016).","DOI":"10.1111\/jnc.13529"},{"key":"54373_CR7","doi-asserted-by":"crossref","unstructured":"Athauda, D. & Foltynie, T. J. N. R. N. The ongoing pursuit of neuroprotective therapies in Parkinson disease, 11 25\u201340. (2015).","DOI":"10.1038\/nrneurol.2014.226"},{"key":"54373_CR8","doi-asserted-by":"crossref","unstructured":"Tambasco, N. & Romoli, M. P.J.C.n. Calabresi, Levodopa in Parkinson\u2019s disease: current status and future developments, 16 1239\u20131252. (2018).","DOI":"10.2174\/1570159X15666170510143821"},{"key":"54373_CR9","doi-asserted-by":"crossref","unstructured":"Salat, D. E.J.J.o.P.s.d. Tolosa, Levodopa in the treatment of Parkinson\u2019s disease: current status and new developments, 3 255\u2013269. (2013).","DOI":"10.3233\/JPD-130186"},{"key":"54373_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/S0317167100026147","volume":"14","author":"A Barbeau","year":"1987","unstructured":"Barbeau, A., Roy, M., Bernier, G., Campanella, G. & Paris, S. Ecogenetics of Parkinson\u2019s disease: Prevalence and environmental aspects in rural areas. Can. J. Neurol. Sci. 14, 36\u201341 (1987).","journal-title":"Can. J. Neurol. Sci."},{"key":"54373_CR11","doi-asserted-by":"crossref","unstructured":"Jankovic, J. L.G.J.N.d. Aguilar, treatment, Current approaches to the treatment of Parkinson\u2019s disease, 4 743\u2013757. (2008).","DOI":"10.2147\/NDT.S2006"},{"key":"54373_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1389202914666131210213042","volume":"15","author":"J Dorszewska","year":"2014","unstructured":"Dorszewska, J., Prendecki, M., Lianeri, M. & Kozubski, W. J. Molecular effects of L-dopa therapy in Parkinson\u2019s disease. Curr. Genomics 15, 11\u201317 (2014).","journal-title":"Curr. Genomics"},{"key":"54373_CR13","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ana.10513","volume":"53","author":"O Rascol","year":"2003","unstructured":"Rascol, O. et al. Limitations of current Parkinson\u2019s disease therapy. Ann. Neurol. 53, S3\u2013S15 (2003).","journal-title":"Ann. Neurol."},{"key":"54373_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejmech.2015.10.028","volume":"107","author":"S Wagner","year":"2016","unstructured":"Wagner, S. et al. Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines. Eur. J. Med. Chem. 107, 97\u2013108 (2016).","journal-title":"Eur. J. Med. Chem."},{"key":"54373_CR15","doi-asserted-by":"crossref","unstructured":"Francis, S. H., Turko, I. V. & Corbin, J. D. Cyclic nucleotide phosphodiesterases: relating structure and function, (2000).","DOI":"10.1016\/S0079-6603(00)65001-8"},{"key":"54373_CR16","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","volume":"96","author":"SH Soderling","year":"1999","unstructured":"Soderling, S. H., Bayuga, S. J. & Beavo, J. A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proceedings of the National Academy of Sciences 96, 7071\u20137076 (1999).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"54373_CR17","doi-asserted-by":"publisher","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","volume":"274","author":"K Fujishige","year":"1999","unstructured":"Fujishige, K. et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem. 274, 18438\u201318445 (1999).","journal-title":"J. Biol. Chem."},{"key":"54373_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd13010023","volume":"13","author":"DE Magouliotis","year":"2026","unstructured":"Magouliotis, D. E. et al. Family-wide dysregulation of phosphodiesterases alters cAMP\/cGMP microdomains in thoracic aortic aneurysm. J. Cardiovasc. Dev. Dis. 13, 23 (2026).","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"54373_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/pro.70472","volume":"35","author":"B Sharma","year":"2026","unstructured":"Sharma, B., Singh, R., Kumar, A., Das, P. & Purohit, R. Expanding the therapeutic landscape of PDE10A inhibition through alchemical absolute binding free energy calculations and in-vitro evaluation. Protein Sci. 35, e70472 (2026).","journal-title":"Protein Sci."},{"key":"54373_CR20","first-page":"54","volume":"8","author":"FS Menniti","year":"2007","unstructured":"Menniti, F. S., Chappie, T. A., Humphrey, J. M. & Schmidt, C. Phosphodiesterase 10A inhibitors: A novel approach to the treatment of the symptoms of schizophrenia. J.J.C.o.i.i.d. 8, 54\u201359 (2007).","journal-title":"J.J.C.o.i.i.d."},{"key":"54373_CR21","first-page":"660","volume":"5","author":"FS Menniti","year":"2006","unstructured":"Menniti, F. S., Faraci, W. S. & Schmidt, C. Phosphodiesterases in the CNS: Targets for drug development. J.J.N.R.D.D. 5, 660\u2013670 (2006).","journal-title":"J.J.N.R.D.D."},{"key":"54373_CR22","first-page":"983","volume":"22","author":"JA d. Siuciak","year":"2008","unstructured":"d. Siuciak, J. A. The role of phosphodiesterases in schizophrenia: Therapeutic implications. J.C.d. 22, 983\u2013993 (2008).","journal-title":"J.C.d."},{"key":"54373_CR23","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1021\/jm040217u","volume":"48","author":"DT Manallack","year":"2005","unstructured":"Manallack, D. T., Hughes, R. A. & Thompson, P. E. J. The next generation of phosphodiesterase inhibitors: Structural clues to ligand and substrate selectivity of phosphodiesterases. J. Med. Chem. 48, 3449\u20133462 (2005).","journal-title":"J. Med. Chem."},{"key":"54373_CR24","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1021\/jm100574m","volume":"53","author":"P Schmidtke","year":"2010","unstructured":"Schmidtke, P. & Barril, X. J. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. J. Med. Chem. 53, 5858\u20135867 (2010).","journal-title":"J. Med. Chem."},{"key":"54373_CR25","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1039\/D1RA07649C","volume":"12","author":"M Al-Nema","year":"2022","unstructured":"Al-Nema, M. et al. Structure-based discovery and bio-evaluation of a cyclopenta [4, 5] thieno [2, 3-d] pyrimidin-4-one as a phosphodiesterase 10A inhibitor. RSC Adv. 12, 1576\u20131591 (2022).","journal-title":"RSC Adv."},{"key":"54373_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2174\/138161211795049624","volume":"17","author":"J Kehler","year":"2011","unstructured":"Kehler, J. & Nielsen, J. PDE10A inhibitors: Novel therapeutic drugs for schizophrenia. Curr. Pharm. Des. 17, 137\u2013150 (2011).","journal-title":"Curr. Pharm. Des."},{"key":"54373_CR27","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1021\/acs.jmedchem.7b00404","volume":"61","author":"F Svensson","year":"2018","unstructured":"Svensson, F., Bender, A. & Bailey, D. Fragment-based drug discovery of phosphodiesterase inhibitors: miniperspective. J. Med. Chem. 61, 1415\u20131424 (2018).","journal-title":"J. Med. Chem."},{"key":"54373_CR28","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/cbdd.13584","volume":"94","author":"EM Jokinen","year":"2019","unstructured":"Jokinen, E. M., Postila, P. A., Ahinko, M., Niinivehmas, S. & Pentik\u00e4inen, O. T. Fragment-and negative image\u2010based screening of phosphodiesterase 10A inhibitors. Chem. Biol. Drug Des. 94, 1799\u20131812 (2019).","journal-title":"Chem. Biol. Drug Des."},{"key":"54373_CR29","doi-asserted-by":"publisher","first-page":"7299","DOI":"10.1021\/jm3004976","volume":"55","author":"TA Chappie","year":"2012","unstructured":"Chappie, T. A., Helal, C. J. & Hou, X. J. Current landscape of phosphodiesterase 10A (PDE10A) inhibition. J. Med. Chem. 55, 7299\u20137331 (2012).","journal-title":"J. Med. Chem."},{"key":"54373_CR30","volume":"214","author":"HS Amin","year":"2021","unstructured":"Amin, H. S., Parikh, P. K. & Ghate, M. D. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors-An update of recent progress. J.E.J.o.M.C. 214, 113155 (2021).","journal-title":"J.E.J.o.M.C."},{"key":"54373_CR31","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty, S. & Jenner, P. J. Animal models of Parkinson\u2019s disease: A source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 164, 1357\u20131391 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"54373_CR32","first-page":"61","volume":"28","author":"E Bezard","year":"2013","unstructured":"Bezard, E., Yue, Z., Kirik, D. & Spillantini, M. G. Animal models of Parkinson\u2019s disease: Limits and relevance to neuroprotection studies. J.M.D. 28, 61\u201370 (2013).","journal-title":"J.M.D."},{"key":"54373_CR33","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1016\/j.bmc.2016.05.049","volume":"24","author":"M Yoshikawa","year":"2016","unstructured":"Yoshikawa, M. et al. Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket. Bioorg. Med. Chem. 24, 3447\u20133455 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"54373_CR34","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.bmcl.2015.03.050","volume":"25","author":"DF Burdi","year":"2015","unstructured":"Burdi, D. F. et al. Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A. Med. Chem. Lett. 25, 1864\u20131868 (2015).","journal-title":"Med. Chem. Lett."},{"key":"54373_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejmech.2018.05.043","volume":"155","author":"R Moszczy\u0144ski-P\u0119tkowski","year":"2018","unstructured":"Moszczy\u0144ski-P\u0119tkowski, R. et al. Synthesis and characterization of novel classes of PDE10A inhibitors \u2212\u20091H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines. Eur. J. Med. Chem. 155, 96\u2013116 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"54373_CR36","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1016\/j.bmc.2014.10.013","volume":"22","author":"RM Rzasa","year":"2014","unstructured":"Rzasa, R. M. et al. Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility. Bioorg. Med. Chem. 22, 6570\u20136585 (2014).","journal-title":"Bioorg. Med. Chem."},{"key":"54373_CR37","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.2174\/0929867325666180309110629","volume":"25","author":"Z Agnieszka","year":"2018","unstructured":"Agnieszka, Z. et al. Phosphodiesterase 10 inhibitors - Novel perspectives for psychiatric and neurodegenerative drug discovery. Curr. Med. Chem. 25, 3455\u20133481 (2018).","journal-title":"Curr. Med. Chem."},{"key":"54373_CR38","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1039\/c4ob01865f","volume":"13","author":"J Ren","year":"2015","unstructured":"Ren, J. et al. Multi-substituted 8-aminoimidazo[1,2-a]pyrazines by Groebke\u2013Blackburn\u2013Bienaym\u00e9 reaction and their Hsp90 inhibitory activity. Org. Biomol. Chem. 13, 1531\u20131535. https:\/\/doi.org\/10.1039\/c4ob01865f (2015).","journal-title":"Org. Biomol. Chem."},{"key":"54373_CR39","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1093\/bib\/bbz103","volume":"21","author":"FE Agamah","year":"2020","unstructured":"Agamah, F. E. et al. Computational\/in silico methods in drug target and lead prediction. Brief. Bioinform. 21, 1663\u20131675 (2020).","journal-title":"Brief. Bioinform."},{"key":"54373_CR40","first-page":"757","volume":"43","author":"A Faris","year":"2025","unstructured":"Faris, A. et al. Dynamics, QSAR-driven screening uncovers and designs novel pyrimidine-4, 6-diamine derivatives as potent JAK3 inhibitors. J.J.o.B.S. 43, 757\u2013786 (2025).","journal-title":"J.J.o.B.S."},{"key":"54373_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44652-z","volume":"13","author":"A Faris","year":"2023","unstructured":"Faris, A. et al. From himachalenes to trans-himachalol: Unveiling bioactivity through hemisynthesis and molecular docking analysis. Sci. Rep. 13, 17653 (2023).","journal-title":"Sci. Rep."},{"key":"54373_CR42","first-page":"54","volume":"16","author":"S Pandey","year":"2020","unstructured":"Pandey, S. & Singh, B. De-novo drug design, molecular docking and in-silico molecular prediction of AChEI analogues through CADD approaches as anti-Alzheimer\u2019s agents. J.C.C.-A.D.D. 16, 54\u201372 (2020).","journal-title":"J.C.C.-A.D.D."},{"key":"54373_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2025.108875","author":"VA Parekh","year":"2026","unstructured":"Parekh, V. A. et al. Identification of phosphodiesterase 10 A modulators for neurodegenerative and psychiatric disorders: Combination of physics-based virtual screening and machine learning approaches. Comput. Biol. Chem. https:\/\/doi.org\/10.1016\/j.compbiolchem.2025.108875 (2026).","journal-title":"Comput. Biol. Chem."},{"key":"54373_CR44","doi-asserted-by":"publisher","first-page":"12887","DOI":"10.1021\/acs.jmedchem.0c01272","volume":"63","author":"G Tresadern","year":"2020","unstructured":"Tresadern, G. et al. [1, 2, 4] Triazolo [1, 5-a] pyrimidine phosphodiesterase 2A inhibitors: structure and free-energy perturbation-guided exploration. J. Med. Chem. 63, 12887\u201312910 (2020).","journal-title":"J. Med. Chem."},{"key":"54373_CR45","doi-asserted-by":"publisher","first-page":"7637","DOI":"10.1039\/C6NJ01038E","volume":"40","author":"AB Ramesha","year":"2016","unstructured":"Ramesha, A. B. et al. A novel approach for the synthesis of imidazo and triazolopyridines from dithioesters. New J. Chem. 40, 7637\u20137642 (2016).","journal-title":"New J. Chem."},{"key":"54373_CR46","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.2174\/0929867325666180309110629","volume":"25","author":"A Zagorska","year":"2018","unstructured":"Zagorska, A. et al. Phosphodiesterase 10 inhibitors-Novel perspectives for psychiatric and neurodegenerative drug discovery. Curr. Med. Chem. 25, 3455\u20133481 (2018).","journal-title":"Curr. Med. Chem."},{"key":"54373_CR47","doi-asserted-by":"publisher","first-page":"D1217","DOI":"10.1093\/nar\/gkx1026","volume":"46","author":"X Zeng","year":"2018","unstructured":"Zeng, X. et al. NPASS: Natural product activity and species source database for natural product research, discovery and tool development. Nucleic Acids Res. 46, D1217\u2013D1222 (2018).","journal-title":"Nucleic Acids Res."},{"key":"54373_CR48","doi-asserted-by":"publisher","unstructured":"RDKit, R. Open-source cheminformatics, (2024). https:\/\/doi.org\/10.5281\/zenodo, 591637.","DOI":"10.5281\/zenodo"},{"key":"54373_CR49","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/1471-2105-14-257","volume":"14","author":"S Beisken","year":"2013","unstructured":"Beisken, S. et al. KNIME-CDK: Workflow-driven cheminformatics. BMC Bioinform. 14, 257 (2013).","journal-title":"BMC Bioinform."},{"key":"54373_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3\u201325 (1997).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"54373_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2019.06.011","volume":"309","author":"O Gerlits","year":"2019","unstructured":"Gerlits, O. et al. A new crystal form of human acetylcholinesterase for exploratory room-temperature crystallography studies. Chem. Biol. Interact. 309, 108698 (2019).","journal-title":"Chem. Biol. Interact."},{"key":"54373_CR52","first-page":"8.12. 11","volume":"18","author":"MP Repasky","year":"2007","unstructured":"Repasky, M. P., Shelley, M. & Friesner, R. A. Flexible ligand docking with Glide. J.C.p.i.b. 18, 8.12. 11-18.12. 36 (2007).","journal-title":"J.C.p.i.b."},{"key":"54373_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10822-007-9163-6","volume":"22","author":"J Kirchmair","year":"2008","unstructured":"Kirchmair, J., Markt, P., Distinto, S., Wolber, G. & Langer, T. Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection\u2014What can we learn from earlier mistakes?. J. Comput. Aided Mol. Des. 22, 213\u2013228 (2008).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"54373_CR54","first-page":"444","volume":"49","author":"KE Hevener","year":"2009","unstructured":"Hevener, K. E. et al. Modeling, validation of molecular docking programs for virtual screening against dihydropteroate synthase. J.J.o.c.i. 49, 444\u2013460 (2009).","journal-title":"J.J.o.c.i."},{"key":"54373_CR55","doi-asserted-by":"crossref","unstructured":"Morehead, A., Giri, N., Liu, J., Neupane, P. & Cheng, J. Assessing the potential of deep learning for protein\u2013ligand docking. Nat. Mach. Intell., 1\u201310. (2025).","DOI":"10.1038\/s42256-025-01160-1"},{"key":"54373_CR56","doi-asserted-by":"crossref","unstructured":"Kuhn, B., Kollman, P. A. & Stahl, M. Prediction of pKa shifts in proteins using a combination of molecular mechanical and continuum solvent calculations, 25 1865\u20131872. (2004).","DOI":"10.1002\/jcc.20111"},{"key":"54373_CR57","doi-asserted-by":"crossref","unstructured":"Kumar, N., Devi, B., Jangid, K. & J.o.B, V. J. Dynamics, Pharmacophore-based virtual screening of the chromone derivatives as potential therapeutic for Alzheimer\u2019s disease, 1\u201315. (2025).","DOI":"10.1080\/07391102.2025.2458327"},{"key":"54373_CR58","first-page":"509","volume":"42","author":"K Jangid","year":"2024","unstructured":"Jangid, K. et al. Virtual screening and molecular dynamics simulation approach for the identification of potential multi-target directed ligands for the treatment of Alzheimer\u2019s disease. Dynamics 42, 509\u2013527 (2024).","journal-title":"Dynamics"},{"key":"54373_CR59","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1016\/j.bmc.2016.06.034","volume":"24","author":"IS Guti\u00e9rrez","year":"2016","unstructured":"Guti\u00e9rrez, I. S. et al. Parametrization of halogen bonds in the CHARMM general force field: Improved treatment of ligand\u2013protein interactions. Bioorg. Med. Chem. 24, 4812\u20134825 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"54373_CR60","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel, D. et al. GROMACS: Fast, flexible, and free. J. Comput. Chem. 26, 1701\u20131718 (2005).","journal-title":"J. Comput. Chem."},{"key":"54373_CR61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 14, 33\u201338 (1996).","journal-title":"J. Mol. Graph."},{"key":"54373_CR62","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/ci500020m","volume":"54","author":"R Kumari","year":"2014","unstructured":"Kumari, R., Kumar, R. & Lynn, A. g_mmpbsa\u2014A GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inf. Model. 54, 1951\u20131962 (2014).","journal-title":"J. Chem. Inf. Model."},{"key":"54373_CR63","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/07391102.2023.2201838","volume":"42","author":"K Jangid","year":"2024","unstructured":"Jangid, K. et al. Virtual screening and molecular dynamics simulation approach for the identification of potential multi-target directed ligands for the treatment of Alzheimer\u2019s disease. J. Biomol. Struct. Dyn. 42, 509\u2013527 (2024).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"54373_CR64","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","volume":"9","author":"AL Hopkins","year":"2004","unstructured":"Hopkins, A. L., Groom, C. R. & Alex, A. Ligand efficiency: a useful metric for lead selection. Drug discovery today. 9, 430\u2013431 (2004).","journal-title":"Drug discovery today"},{"key":"54373_CR65","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13321-019-0330-2","volume":"11","author":"PW Kenny","year":"2019","unstructured":"Kenny, P. W. The nature of ligand efficiency. J. Cheminform. 11, 8 (2019).","journal-title":"J. Cheminform."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54373-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54373-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54373-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:02:50Z","timestamp":1791543770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54373-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54373"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54373-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31545"}}